PROGRAF INJECTION Rx
Generic Name and Formulations:
Tacrolimus 5mg/mL; soln for IV infusion after dilution; contains polyoxyl 60 hydrogenated castor oil.
Astellas Pharma US, Inc.
Indications for PROGRAF INJECTION:
Organ rejection prophylaxis in allogeneic hepatic transplant patients, in combination with corticosteroids; or in cardiac and renal transplant patients in combination with corticosteroids, azathioprine, or mycophenolate mofetil (MMF).
Limitations Of use:
Do not use simultaneously with cyclosporine. Reserve IV inj for patients unable to take oral caps. Concomitant sirolimus: not recommended in liver/heart transplant; safety and efficacy not established in kidney transplant.
Give at least 6hrs after transplantation if unable to tolerate oral capsules. Cardiac: initially 0.01mg/kg/day. Hepatic or renal: initially 0.03–0.05mg/kg/day. All: give by continuous IV infusion until capsules can be tolerated (usually 2–3 days). Monitor patient for first 30 minutes of infusion and at frequent intervals thereafter. Concomitant corticosteroid is recommended early post-transplantation. Renal or hepatic impairment: use lowest effective dose (see full labeling). Post-op oliguria: may delay therapy until renal function recovers.
Give at least 6hrs after transplantation if unable to tolerate oral capsules. Hepatic: Initially 0.03–0.05mg/kg/day by continuous IV infusion until capsules can be tolerated (usually 2–3 days). Monitor patient for first 30 minutes of infusion and at frequent intervals thereafter.
Increased risk of lymphomas and other malignancies (eg, skin) due to immunosuppression. Avoid sun, UV light. Increased risk of infections (eg, bacterial, viral, fungal, protozoal, cytomegalovirus), opportunistic infections including polyoma virus. Only physicians experienced in immunosuppressive therapy and transplant management should prescribe Prograf. Diabetes: monitor for hyperglycemia. Hepatic or renal impairment; monitor and consider dose reduction. Obtain tacrolimus blood concentrations, serum creatinine, potassium, and fasting glucose periodically. Avoid in congenital long QT syndrome. CHF, bradyarrhythmias, concomitant antiarrhythmic drugs, or electrolyte disturbances; consider obtaining ECGs and monitor electrolytes periodically. Discontinue or reduce dose if myocardial hypertrophy occurs. Pregnancy (Cat.C), nursing mothers: not recommended.
Concomitant sirolimus (see Indications), live vaccines: not recommended. Concomitant strong CYP3A4 inhibitors/inducers or substrates: must adjust dosing regimen, closely monitor tacrolimus blood concentrations and for QT prolongation. Avoid potassium-sparing diuretics, grapefruit juice, nelfinavir. Additive nephrotoxicity with cyclosporine (discontinue at least 24hrs prior to initiating the other drug), aminoglycosides, ganciclovir, amphotericin B, cisplatin. May be potentiated by calcium channel blockers (eg, diltiazem, nifedipine), antifungals (eg, fluconazole, ketoconazole), macrolides (eg, troleandomycin, clarithromycin, erythromycin), metoclopramide, lansoprazole, omeprazole, bromocriptine, chloramphenicol, cimetidine, cyclosporine, danazol, ethinyl estradiol, amiodarone, methylprednisolone, schisandra sphenanthera extract, protease inhibitors (eg, telaprevir, boceprevir, ritonavir), nefazodone, magnesium-aluminum-hydroxide. May be antagonized by carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, caspofungin, St. Johns Wort, sirolimus. Caution with mycophenolic acid.
Tremor, headache, constipation, diarrhea, nausea, insomnia, hypertension, renal dysfunction, infections (eg,viral, cytomegalovirus, polyoma virus), hypophosphatemia, hyperkalemia, hypomagnesemia, hyperglycemia, nephrotoxicity or neurotoxicity (esp. in high doses), JC virus-associated progressive multifocal leukoencephalopathy, post-transplant diabetes mellitus, posterior reversible encephalopathy syndrome (consider reduced dose or discontinue), malignancies (eg, lymphomas, skin), post-transplant lymphoproliferative disorder, myocardial hypertrophy, pure red cell aplasia, Torsade de Pointes, GI perforation; IV: anaphylactic reactions.
Hepatic (CYP3A4); 99% protein bound.
Fecal (primary), renal.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Nicotinamide and Cancer
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML